JP2009530299A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009530299A5 JP2009530299A5 JP2009500498A JP2009500498A JP2009530299A5 JP 2009530299 A5 JP2009530299 A5 JP 2009530299A5 JP 2009500498 A JP2009500498 A JP 2009500498A JP 2009500498 A JP2009500498 A JP 2009500498A JP 2009530299 A5 JP2009530299 A5 JP 2009530299A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- patient
- compound
- health
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78307006P | 2006-03-15 | 2006-03-15 | |
| PCT/US2007/006606 WO2007106585A1 (en) | 2006-03-15 | 2007-03-15 | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013219882A Division JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009530299A JP2009530299A (ja) | 2009-08-27 |
| JP2009530299A5 true JP2009530299A5 (enExample) | 2010-04-02 |
Family
ID=38222520
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009500498A Withdrawn JP2009530299A (ja) | 2006-03-15 | 2007-03-15 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2015236260A Active JP6224059B2 (ja) | 2006-03-15 | 2015-12-03 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013219882A Withdrawn JP2014015484A (ja) | 2006-03-15 | 2013-10-23 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2015236260A Active JP6224059B2 (ja) | 2006-03-15 | 2015-12-03 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2017028811A Withdrawn JP2017082017A (ja) | 2006-03-15 | 2017-02-20 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2018139327A Withdrawn JP2018165277A (ja) | 2006-03-15 | 2018-07-25 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2019185225A Withdrawn JP2020002176A (ja) | 2006-03-15 | 2019-10-08 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2021023314A Withdrawn JP2021073319A (ja) | 2006-03-15 | 2021-02-17 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2022211659A Withdrawn JP2023026536A (ja) | 2006-03-15 | 2022-12-28 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
| JP2025091052A Pending JP2025120217A (ja) | 2006-03-15 | 2025-05-30 | 補体のインヒビターによる発作性夜間血色素尿症患者の処置 |
Country Status (16)
| Country | Link |
|---|---|
| US (8) | US20090220508A1 (enExample) |
| EP (5) | EP3124029A1 (enExample) |
| JP (9) | JP2009530299A (enExample) |
| KR (2) | KR20140057635A (enExample) |
| AU (1) | AU2007225044C1 (enExample) |
| BR (2) | BR122017024057B8 (enExample) |
| CA (2) | CA2645810C (enExample) |
| DK (1) | DK2359834T5 (enExample) |
| ES (2) | ES2965283T3 (enExample) |
| HU (2) | HUE030105T2 (enExample) |
| IL (4) | IL302157A (enExample) |
| MX (2) | MX340784B (enExample) |
| PL (2) | PL2359834T3 (enExample) |
| PT (1) | PT2359834T (enExample) |
| SI (1) | SI2359834T1 (enExample) |
| WO (1) | WO2007106585A1 (enExample) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| BRPI0517837A (pt) | 2004-11-12 | 2008-10-21 | Xencor Inc | variantes fc com ligação alterada a fcrn |
| ES2965283T3 (es) | 2006-03-15 | 2024-05-28 | Alexion Pharma Inc | Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento |
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| AU2008345242B2 (en) * | 2007-10-31 | 2014-02-27 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| EP2275443B1 (en) | 2008-04-11 | 2015-12-02 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| US9447176B2 (en) * | 2008-11-10 | 2016-09-20 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
| MX2012005388A (es) * | 2009-11-09 | 2012-07-23 | Alexion Pharma Inc | Reactivos y metodos para detectar globulos blancos pnh tipo ii y su identificacion como factores de riesgo para transtornos trombolicos. |
| WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
| TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| TWI654204B (zh) | 2010-11-30 | 2019-03-21 | Chugai Seiyaku Kabushiki Kaisha | 具有鈣依存性的抗原結合能力之抗體 |
| CA2827170A1 (en) | 2011-02-11 | 2012-08-16 | David M. Hilbert | Monovalent and multivalent multispecific complexes and uses thereof |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| ES2728278T3 (es) | 2011-12-21 | 2019-10-23 | Novartis Ag | Composiciones que comprenden anticuerpos dirigidos al factor P y C5 |
| RS58503B1 (sr) | 2012-02-20 | 2019-04-30 | Swedish Orphan Biovitrum Ab Publ | Polipeptidi koji se vezuju za humani komplement c5 |
| WO2013137912A2 (en) * | 2012-03-16 | 2013-09-19 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| EP3473272A1 (en) * | 2013-03-29 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| KR102497083B1 (ko) | 2013-08-28 | 2023-02-07 | 애피바디 에이비 | 돌연변이된 스캐폴드를 갖는 결합 폴리펩티드 |
| JP6767865B2 (ja) | 2013-08-28 | 2020-10-14 | スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル） | ヒト補体ｃ５に結合する安定なポリペプチド |
| WO2015054569A1 (en) | 2013-10-10 | 2015-04-16 | Viropharma Holdings Limited | Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein |
| NZ711451A (en) * | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| HUE045646T2 (hu) | 2014-06-12 | 2020-01-28 | Ra Pharmaceuticals Inc | Komplement aktivitás modulálása |
| SG10201913611QA (en) | 2014-08-08 | 2020-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
| EP3682879B1 (en) | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| JP6778185B2 (ja) * | 2014-10-15 | 2020-10-28 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 細胞を培養する方法 |
| JP6479974B2 (ja) | 2014-10-15 | 2019-03-06 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 大規模エクリズマブ産生細胞培養を再現する方法 |
| US9908932B2 (en) | 2014-10-15 | 2018-03-06 | Alexion Pharmaceuticals, Inc. | Methods of shifting an isoelectric profile of a protein product and uses thereof |
| ES2809455T3 (es) | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| SG10201710322VA (en) | 2014-12-19 | 2018-02-27 | Chugai Pharmaceutical Co Ltd | Anti-c5 antibodies and methods of use |
| NZ730607A (en) | 2014-12-19 | 2022-07-01 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| CN107428823B (zh) | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
| WO2016123371A1 (en) | 2015-01-28 | 2016-08-04 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| WO2016154290A1 (en) | 2015-03-23 | 2016-09-29 | Alexion Pharmaceuticals, Inc. | Virus filtration |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| WO2016160756A2 (en) * | 2015-03-31 | 2016-10-06 | Alexion Pharmaceuticlas, Inc. | Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patents |
| WO2016164308A1 (en) | 2015-04-06 | 2016-10-13 | Subdomain, Llc | De novo binding domain containing polypeptides and uses thereof |
| EP3991748A3 (en) | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| EP3307318A4 (en) | 2015-06-09 | 2019-01-16 | Children's Hospital Medical Center | DOSAGE ALGORITHM FOR COMPLEMENT INHIBITOR |
| US11174313B2 (en) | 2015-06-12 | 2021-11-16 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| KR20180033502A (ko) | 2015-06-12 | 2018-04-03 | 알렉터 엘엘씨 | 항-cd33 항체 및 그의 사용 방법 |
| WO2016209956A1 (en) * | 2015-06-26 | 2016-12-29 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| EP3341411B1 (en) | 2015-08-28 | 2025-06-11 | Alector LLC | Anti-siglec-7 antibodies and methods of use thereof |
| WO2017044811A1 (en) | 2015-09-11 | 2017-03-16 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| KR102777500B1 (ko) | 2015-09-23 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | 최적화된 항-cd3 이중특이적 항체 및 이의 용도 |
| EP3359569A2 (en) | 2015-10-06 | 2018-08-15 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
| EP3359566A1 (en) | 2015-10-07 | 2018-08-15 | Alexion Pharmaceuticals, Inc. | A method for treating age-related macular degeneration in a patient |
| SG11201803567XA (en) | 2015-10-29 | 2018-05-30 | Alector Llc | Anti-siglec-9 antibodies and methods of use thereof |
| EP4218790B1 (en) * | 2015-12-16 | 2026-02-18 | UCB Holdings, Inc. | Modulators of complement activity |
| MX2022006069A (es) | 2016-01-14 | 2023-01-12 | Chemocentryx Inc | Metodo para tratar glomerulopatia c3. |
| US11472877B2 (en) | 2016-03-04 | 2022-10-18 | Alector Llc | Anti-TREM1 antibodies and methods of use thereof |
| CA3015277A1 (en) | 2016-03-10 | 2017-09-14 | Acceleron Pharma Inc. | Activin type 2 receptor binding proteins and uses thereof |
| CN116217731B (zh) | 2016-04-22 | 2025-12-30 | 艾科赛扬制药股份有限公司 | Alk7结合蛋白及其用途 |
| AU2017269839A1 (en) | 2016-05-27 | 2018-11-22 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| WO2017218515A1 (en) | 2016-06-14 | 2017-12-21 | Regeneron Pharmaceuticals, Inc. | Anti-c5 antibodies and uses thereof |
| BR112019001902A2 (pt) | 2016-08-05 | 2019-07-09 | Chugai Seiyaku Kabushiki Kaisha | composição para profilaxia ou tratamento de doenças relacionadas à il-8 |
| EP3529618B1 (en) | 2016-10-19 | 2020-12-02 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5 in a sample |
| CA3045114A1 (en) | 2016-12-07 | 2018-06-14 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
| AU2017376884B2 (en) * | 2016-12-16 | 2024-10-03 | Samsung Bioepis Co., Ltd | Stable aqueous anti-C5 antibody composition |
| CR20190403A (es) | 2017-01-31 | 2019-10-10 | Hoffmann La Roche | Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| KR102632860B1 (ko) | 2017-03-01 | 2024-02-02 | 아칠리온 파르마세우티칼스 인코포레이티드 | 의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물 |
| WO2018213316A1 (en) | 2017-05-16 | 2018-11-22 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
| WO2018217638A1 (en) | 2017-05-22 | 2018-11-29 | Alexion Pharmaceuticals Inc. | Dosage and administration of anti-c5 antibodies for treatment of protein-losing enteropathy in patients |
| EP3634466A4 (en) | 2017-06-06 | 2021-03-24 | Relinia, Inc. | MONOCATENARY TNF RECEPTOR 2 AGONIST FUSION PROTEINS |
| BR112020001703B1 (pt) | 2017-07-27 | 2024-01-02 | Alexion Pharmaceuticals, Inc | Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | THERAPY PLANS FOR TREATMENT OF PAROXYSMALER NIGHTLY HEMOGLOBINURIA |
| MA47691A (fr) | 2017-08-03 | 2020-01-08 | Alector Llc | Anticorps anti-cd33 et leurs procédés d'utilisation |
| TWI868807B (zh) | 2017-08-03 | 2025-01-01 | 美商阿列克特有限責任公司 | 抗trem2抗體及其使用方法 |
| EP3700928A1 (en) | 2017-10-26 | 2020-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| BR112020009136A2 (pt) | 2017-11-14 | 2020-10-13 | Arcellx, Inc. | polipeptídeos que contêm domínio d e usos dos mesmos |
| US12037389B2 (en) | 2017-12-01 | 2024-07-16 | Children's Hospital Medical Center | Compositions for interferon blockade and methods of using same |
| KR20200095485A (ko) * | 2017-12-04 | 2020-08-10 | 라 파마슈티컬스 인코포레이티드 | 보체 활성의 조절인자 |
| MX2020006113A (es) | 2017-12-13 | 2020-08-24 | Regeneron Pharma | Combinaciones de anticuerpos anti-c5 y usos de las mismas. |
| CN111886246B (zh) | 2017-12-29 | 2024-12-17 | 艾莱克特有限责任公司 | 抗tmem106b抗体及其使用方法 |
| CN111971301B (zh) | 2018-01-31 | 2025-01-07 | 艾莱克特有限责任公司 | 抗ms4a4a抗体及其使用方法 |
| US20190247560A1 (en) | 2018-02-13 | 2019-08-15 | Gambro Lundia Ab | Extracorporeal devices and methods of treating complement factor related diseases |
| MX2020011828A (es) | 2018-05-25 | 2021-02-09 | Alector Llc | Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos. |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| AU2019282778A1 (en) | 2018-06-08 | 2020-12-10 | Alector Llc | Anti-Siglec-7 antibodies and methods of use thereof |
| KR20210035173A (ko) * | 2018-06-19 | 2021-03-31 | 아타르가, 엘엘씨 | 보체 성분 5에 대한 항체분자 및 이의 용도 |
| EP3814373A1 (en) | 2018-06-28 | 2021-05-05 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-c5 antibodies |
| CN119912569A (zh) | 2018-06-29 | 2025-05-02 | 艾利妥 | 抗SIRP-β1抗体及其使用方法 |
| PT3618928T (pt) | 2018-07-13 | 2023-03-29 | Alector Llc | Anticorpos anti-sortilina e métodos de utilização dos mesmos |
| EA202190183A1 (ru) | 2018-07-27 | 2021-05-18 | Алектор Ллс | Антитела к siglec-5 и способы их применения |
| IL280475B2 (en) | 2018-08-01 | 2026-04-01 | Chugai Pharmaceutical Co Ltd | Pharmaceutical preparation for use in the treatment or prevention of a C5-related disease and a method for treating or preventing a C5-related disease |
| BR112021003016A2 (pt) | 2018-08-31 | 2021-05-18 | Alector Llc | anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um anticorpo e para prevenir, reduzir o risco ou tratar uma doença e composição farmacêutica |
| PT3844189T (pt) | 2018-08-31 | 2025-01-29 | Regeneron Pharma | Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20 |
| US11814363B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Morphic forms of danicopan |
| EP3846803A4 (en) | 2018-09-06 | 2022-08-10 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| EP3856164B1 (en) | 2018-09-25 | 2024-08-07 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| MX2021004994A (es) | 2018-10-30 | 2021-06-15 | Alexion Pharma Inc | Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh). |
| BR112021011727A2 (pt) | 2018-12-17 | 2021-08-31 | Achillion Pharmaceuticals, Inc | Dosagem direcionada para o tratamento de distúrbios mediados do complemento |
| WO2020198062A1 (en) | 2019-03-22 | 2020-10-01 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| US12558398B2 (en) | 2019-06-04 | 2026-02-24 | Ucb Holdings, Inc. | Inflammatory disease treatment with complement inhibitors |
| CN114423450B (zh) | 2019-06-11 | 2025-08-01 | 艾利妥有限责任公司 | 用于疗法中的抗分拣蛋白抗体 |
| CN115068604A (zh) | 2019-07-31 | 2022-09-20 | 豪夫迈·罗氏有限公司 | 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案 |
| CA3144921A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
| WO2021022083A2 (en) | 2019-07-31 | 2021-02-04 | Alector Llc | Anti-ms4a4a antibodies and methods of use thereof |
| WO2021026160A1 (en) | 2019-08-05 | 2021-02-11 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis with eculizumab |
| JP2023505279A (ja) | 2019-12-05 | 2023-02-08 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体の使用方法 |
| WO2021118999A1 (en) | 2019-12-09 | 2021-06-17 | Alexion Pharmaceuticals, Inc. | Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder |
| EP4073119A1 (en) | 2019-12-12 | 2022-10-19 | Alector LLC | Methods of use of anti-cd33 antibodies |
| AU2020401319A1 (en) | 2019-12-13 | 2022-06-30 | Alector Llc | Anti-MerTK antibodies and methods of use thereof |
| WO2021173565A1 (en) | 2020-02-24 | 2021-09-02 | Alector Llc | Methods of use of anti-trem2 antibodies |
| EP4126937A1 (en) | 2020-03-31 | 2023-02-08 | Alector LLC | Anti-mertk antibodies and methods of use thereof |
| IL296992A (en) | 2020-04-03 | 2022-12-01 | Alector Llc | Methods for using anti-trem2 antibodies |
| JP2023522208A (ja) | 2020-04-16 | 2023-05-29 | アシスタンス ピュブリック－オピト ド パリ | ウイルスによって引き起こされる補体媒介性障害を処置する方法 |
| WO2021231470A1 (en) | 2020-05-12 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Use of complement factor d inhibitors alone or in combination with anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria |
| CN116194478A (zh) | 2020-06-24 | 2023-05-30 | 阿雷克森制药公司 | 皮下（sc）施用抗c5抗体治疗补体相关病症 |
| CA3202986A1 (en) | 2020-12-02 | 2022-06-09 | Alector Llc | Methods of use of anti-sortilin antibodies |
| EP4308606A1 (en) | 2021-03-18 | 2024-01-24 | Alector LLC | Anti-tmem106b antibodies and methods of use thereof |
| JP2024511610A (ja) | 2021-03-23 | 2024-03-14 | アレクトル エルエルシー | コロナウイルス感染の治療及び予防のための抗ｔｍｅｍ１０６ｂ抗体 |
| EP4348263A1 (en) | 2021-05-28 | 2024-04-10 | Alexion Pharmaceuticals, Inc. | Methods for detecting cm-tma biomarkers |
| JP2024527262A (ja) | 2021-06-16 | 2024-07-24 | アレクトル エルエルシー | 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法 |
| JP2024527493A (ja) | 2021-06-16 | 2024-07-25 | アレクトル エルエルシー | 一価の抗ＭｅｒＴＫ抗体及びその使用方法 |
| WO2023023220A1 (en) | 2021-08-20 | 2023-02-23 | Alexion Pharmaceuticals, Inc. | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor |
| WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
| WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
| KR20230105972A (ko) * | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| JP2025508757A (ja) | 2022-02-23 | 2025-04-10 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体の使用方法 |
| JP2025524628A (ja) | 2022-07-12 | 2025-07-30 | シートムエックス セラピューティクス，インコーポレイテッド | Ｅｐｃａｍイムノコンジュゲート及びその使用 |
| MA71628A (fr) | 2022-07-29 | 2025-05-30 | Alector Llc | Anticorps anti-gpnmb et leurs méthodes d'utilisation |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
| JP2026503002A (ja) | 2023-01-06 | 2026-01-27 | アレクトル エルエルシー | 抗ｉｌ１８結合タンパク質抗体及びその使用方法 |
| WO2025072726A1 (en) | 2023-09-29 | 2025-04-03 | Trex Bio, Inc. | Tnf-alpha variant fusion molecules |
| WO2025094146A1 (en) | 2023-11-02 | 2025-05-08 | Immunogen Switzerland Gmbh | Vasconstrictors for reducing ocular toxicity of antibody-maytansinoid conjugates |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4686100A (en) * | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| US5705732A (en) | 1989-06-12 | 1998-01-06 | Oklahoma Medical Research Foundation | Universal donor cells |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE3924924A1 (de) | 1989-07-27 | 1991-02-07 | Goetze Otto | Verfahren zum nachweis und/oder der quantitativen bestimmung von komplementpeptid c5a und/oder c5adesarg |
| CA2097825A1 (en) | 1990-12-06 | 1992-06-07 | Henry C. Marsh, Jr. | Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US6329509B1 (en) | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US6027725A (en) | 1991-11-25 | 2000-02-22 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5456909A (en) | 1992-08-07 | 1995-10-10 | T Cell Sciences, Inc. | Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo |
| PT744958E (pt) | 1994-01-31 | 2003-11-28 | Univ Boston | Bancos de anticorpos policlonais |
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| ES2252746T3 (es) | 1994-09-23 | 2006-05-16 | Alexion Pharmaceuticals, Inc. | Procedimientos para el tratamiento de la enfermedad inflamatoria articular. |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
| US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP1253946A2 (en) | 2000-02-10 | 2002-11-06 | Alexion Pharmaceuticals, Inc. | Mixtures of caspase inhibitors and complement inhibitors and methods of use thereof |
| EP2113516B1 (en) | 2000-10-10 | 2014-05-21 | Genentech, Inc. | Antibodies against C5 inhibiting type II endothelial cell activation |
| US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| AU2002234001B2 (en) * | 2000-12-05 | 2008-05-01 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
| US20040253242A1 (en) | 2000-12-05 | 2004-12-16 | Bowdish Katherine S. | Rationally designed antibodies |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| JP2004536138A (ja) | 2001-07-26 | 2004-12-02 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 認識機能を改善する方法 |
| CA2457461C (en) | 2001-08-17 | 2013-12-24 | Tanox, Inc. | Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
| WO2003081206A2 (en) * | 2002-03-18 | 2003-10-02 | Alexion Pharmaceuticals, Inc. | Stratification of patient populations having or suspected of having rheumatoid arthritis |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| EP2314629B2 (en) | 2002-07-18 | 2022-11-16 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US20040091490A1 (en) | 2002-08-28 | 2004-05-13 | Robert Johnson | Stable pH optimized formulation of a modified antibody |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| WO2004029207A2 (en) | 2002-09-27 | 2004-04-08 | Xencor Inc. | Optimized fc variants and methods for their generation |
| KR20110017020A (ko) | 2002-10-17 | 2011-02-18 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| US20040146948A1 (en) | 2002-10-18 | 2004-07-29 | Centenary Institute Of Cancer Medicine And Cell Biology | Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments |
| JP4589123B2 (ja) | 2002-12-16 | 2010-12-01 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | パーソナルビデオレコーダ、記録方法及びユーザインタフェース |
| US7361339B2 (en) * | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| EP1589996A4 (en) | 2003-01-30 | 2009-01-21 | Medimmune Inc | ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULATIONS AND ITS USES |
| AU2004210679A1 (en) | 2003-02-10 | 2004-08-26 | Elan Pharmaceuticals, Inc. | Immunoglobulin formulation and method of preparation thereof |
| AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
| AU2004234377A1 (en) * | 2003-04-25 | 2004-11-11 | Immunex Corporation | Inducers of recombinant protein expression |
| JP2007501021A (ja) | 2003-05-30 | 2007-01-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 遺伝子操作された定常領域を含む、抗体および融合タンパク質 |
| AU2004245038A1 (en) | 2003-06-02 | 2004-12-16 | Alexion Pharmaceuticals, Inc. | De-immunized anti-CD3 antibody |
| US20050027166A1 (en) | 2003-06-17 | 2005-02-03 | Shinya Matsumoto | Endoscope system for fluorescent observation |
| AT412877B (de) | 2003-07-01 | 2005-08-25 | Miba Gleitlager Gmbh | Schichtwerkstoff |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| ATE531388T1 (de) | 2004-03-24 | 2011-11-15 | Abbott Biotherapeutics Corp | Verwendung von anti-alpha5beta1-antikörpern zur hemmung der krebszellproliferation |
| NZ551308A (en) | 2004-05-14 | 2009-06-26 | Alexion Pharma Inc | Prolongation of survival of an allograft by inhibiting complement activity |
| WO2006003179A2 (en) | 2004-07-01 | 2006-01-12 | Novo Nordisk A/S | Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use |
| EP1771565B1 (en) | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivatives |
| ZA200709956B (en) | 2005-05-20 | 2009-02-25 | Genentech Inc | Pretreatment of a biological sample from an autoimmune disease subject |
| WO2007002571A2 (en) | 2005-06-23 | 2007-01-04 | Alexion Pharmaceuticals, Inc. | Use of an anti c5 complement antibody to treat patients with sickle cell disease |
| WO2007005612A2 (en) | 2005-07-01 | 2007-01-11 | Medimmune, Inc. | An integrated approach for generating multidomain protein therapeutics |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| AU2007224250B2 (en) | 2006-03-02 | 2012-05-03 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| ES2965283T3 (es) | 2006-03-15 | 2024-05-28 | Alexion Pharma Inc | Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento |
| EP2013235A1 (en) | 2006-05-01 | 2009-01-14 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency |
| KR101503540B1 (ko) | 2006-09-05 | 2015-03-17 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항체 매개된 신경병증의 치료를 위한 방법과 조성물 |
| WO2011155607A1 (ja) | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
-
2007
- 2007-03-15 ES ES16195355T patent/ES2965283T3/es active Active
- 2007-03-15 WO PCT/US2007/006606 patent/WO2007106585A1/en not_active Ceased
- 2007-03-15 CA CA2645810A patent/CA2645810C/en active Active
- 2007-03-15 EP EP16172335.8A patent/EP3124029A1/en not_active Ceased
- 2007-03-15 MX MX2008011735A patent/MX340784B/es active IP Right Grant
- 2007-03-15 HU HUE11001632A patent/HUE030105T2/en unknown
- 2007-03-15 EP EP23198329.7A patent/EP4316465A3/en active Pending
- 2007-03-15 EP EP11001632.6A patent/EP2359834B1/en not_active Revoked
- 2007-03-15 EP EP16195355.9A patent/EP3167888B1/en active Active
- 2007-03-15 HU HUE16195355A patent/HUE066795T2/hu unknown
- 2007-03-15 SI SI200731886T patent/SI2359834T1/sl unknown
- 2007-03-15 EP EP07753249A patent/EP2001490A1/en not_active Ceased
- 2007-03-15 US US12/225,040 patent/US20090220508A1/en not_active Abandoned
- 2007-03-15 BR BR122017024057A patent/BR122017024057B8/pt active IP Right Grant
- 2007-03-15 DK DK11001632.6T patent/DK2359834T5/en active
- 2007-03-15 KR KR1020147008290A patent/KR20140057635A/ko not_active Ceased
- 2007-03-15 PL PL11001632T patent/PL2359834T3/pl unknown
- 2007-03-15 CA CA3022097A patent/CA3022097C/en active Active
- 2007-03-15 BR BRPI0708909A patent/BRPI0708909B8/pt active IP Right Grant
- 2007-03-15 IL IL302157A patent/IL302157A/en unknown
- 2007-03-15 KR KR1020087024657A patent/KR20080110800A/ko not_active Ceased
- 2007-03-15 AU AU2007225044A patent/AU2007225044C1/en active Active
- 2007-03-15 PL PL16195355.9T patent/PL3167888T3/pl unknown
- 2007-03-15 PT PT110016326T patent/PT2359834T/pt unknown
- 2007-03-15 JP JP2009500498A patent/JP2009530299A/ja not_active Withdrawn
- 2007-03-15 ES ES11001632.6T patent/ES2612118T3/es active Active
-
2008
- 2008-09-11 IL IL194041A patent/IL194041A/en active IP Right Grant
- 2008-09-12 MX MX2022002589A patent/MX2022002589A/es unknown
-
2012
- 2012-03-22 US US13/426,973 patent/US20120237515A1/en not_active Abandoned
-
2013
- 2013-10-23 JP JP2013219882A patent/JP2014015484A/ja not_active Withdrawn
-
2015
- 2015-12-03 JP JP2015236260A patent/JP6224059B2/ja active Active
-
2016
- 2016-05-06 US US15/148,839 patent/US9718880B2/en active Active
- 2016-09-09 US US15/260,888 patent/US9725504B2/en active Active
- 2016-10-03 US US15/284,015 patent/US9732149B2/en active Active
-
2017
- 2017-02-20 JP JP2017028811A patent/JP2017082017A/ja not_active Withdrawn
- 2017-05-14 IL IL252260A patent/IL252260B/en active IP Right Grant
- 2017-07-05 US US15/642,096 patent/US10590189B2/en active Active
-
2018
- 2018-04-08 IL IL258548A patent/IL258548A/en unknown
- 2018-07-25 JP JP2018139327A patent/JP2018165277A/ja not_active Withdrawn
-
2019
- 2019-10-08 JP JP2019185225A patent/JP2020002176A/ja not_active Withdrawn
-
2020
- 2020-01-23 US US16/750,978 patent/US20200392216A1/en not_active Abandoned
- 2020-02-28 US US16/804,567 patent/US10703809B1/en active Active
-
2021
- 2021-02-17 JP JP2021023314A patent/JP2021073319A/ja not_active Withdrawn
-
2022
- 2022-12-28 JP JP2022211659A patent/JP2023026536A/ja not_active Withdrawn
-
2025
- 2025-05-30 JP JP2025091052A patent/JP2025120217A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7257374B2 (ja) | Ｔ制御性細胞の増殖または枯渇方法 | |
| JP2022521591A (ja) | 腎障害の治療 | |
| Sekijima et al. | Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses | |
| Zhang et al. | Deletion of interleukin-6 alleviated interstitial fibrosis in streptozotocin-induced diabetic cardiomyopathy of mice through affecting TGFβ1 and miR-29 pathways | |
| US20260123613A1 (en) | Mouse model of ditra disease and uses thereof | |
| CN113677706B (zh) | 肝毒性的治疗 | |
| JP2011126917A (ja) | 溶血性疾患の処置方法 | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| Sozo et al. | Repeated ethanol exposure during late gestation alters the maturation and innate immune status of the ovine fetal lung | |
| KR20200093533A (ko) | Smc 매개성 질환의 치료 | |
| RU2013130002A (ru) | Композиции и способы лечения симптомов, ассоциированных с амилоидными бляшками | |
| Yang et al. | Eukaryotic translation initiation factor 3 subunit G promotes human colorectal cancer | |
| Shokoples et al. | Angiotensin II-induced a steeper blood pressure elevation in IL-23 receptor-deficient mice: Role of interferon-γ-producing T cells | |
| CN105727295B (zh) | Wip1抑制剂的医学用途 | |
| RU2012105528A (ru) | Применение ингибиторов nkg2d для лечения сердечно-сосудистых и метаболических заболеваний, таких как диабет 2 типа | |
| RU2016125513A (ru) | Способ лечения нефропатии | |
| Tsai et al. | Porphyromonas gingivalis GroEL exacerbates orthotopic allograft transplantation vasculopathy via impairment of endothelial cell function | |
| CA3177998A1 (en) | Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor | |
| WO2023023227A1 (en) | Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors | |
| US20180134782A1 (en) | Use of Macrophage inflammatory protein-1Beta (MIP-1Beta) inhibitor to protect pancreas and prevent blood sugar from rising | |
| WO2023001305A1 (zh) | 缓解或治疗纤维化性疾病的药物组合物或药盒及其应用 | |
| JPWO2017043630A1 (ja) | 筋力低下症および代謝性疾患の治療薬 | |
| JP2019510009A (ja) | Ｓｍｏｃ２を標的化する線維症のための治療方法 | |
| JP6959913B2 (ja) | 肝分泌型代謝制御因子阻害作用による肥満関連疾患治療剤 | |
| US20250215435A1 (en) | Anti-helicase therapy for treatment of repeat expansion disease |